KALA Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 jul 2024 @ 18:59):
Our systems believe the stock currently is overvalued by -0.49% compare to its pairs and should correct downwards.

Stats
Dagens volum	263 739
Gjennomsnittsvolum	225 077
Markedsverdi	19.69M
EPS	$-4.20 ( Q1 \| 2024-05-14 )
Neste inntjeningsdato	( $-4.41 ) 2024-08-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.480 (Sector) 42.63 (Industry) 0
ATR14	$0.0480 (0.69%)

ACOR -24.02%

ACRX 7.50%

ADMP 0.85%

ADMS 0.00%

AGRX 0.71%

AKAN -1.69%

ALIM -0.54%

AMPH -4.03%

AMYT 0.00%

ANIP -0.53%

AQST -6.73%

ASRT -1.61%

ATNX 0.00%

AVDL -1.88%

AYTU -1.03%

BFRI -0.89%

BGXX 8.34%

CLVR 0.00%

COLL 0.90%

CPIX -3.92%

CRDL -1.49%

CRON -1.29%

CYTH -3.40%

DCPH 0.00%

DERM -3.74%

DRRX 1.55%

DVAX -0.45%

EGRX -4.11%

EMBC -2.40%

EMBCV -9.33%

EOLS 1.94%

ESPR 8.33%

EVOK -4.54%

FLGC -1.97%

FLXN 0.00%

GHSI -1.68%

HCM 3.10%

HROW 0.91%

HUGE -4.51%

IMCC -4.11%

INCR 1.99%

IRWD 0.54%

ITCI -2.28%

IXHL 0.34%

JUPW 11.76%

KALA -1.44%

KIN 0.11%

KMDA -1.20%

LNTH -0.46%

NBIX 1.04%

NEPT 0.00%

NLTX 1.45%

OGI 0.32%

OPTN 0.96%

ORGO -3.21%

PAHC 1.97%

PCRX 0.45%

PETQ 0.36%

PLXP 0.00%

PPD 0.00%

PROC -0.32%

PRPH -1.91%

PTPI -1.88%

RDHL -0.05%

RDUS 0.13%

REPH -0.48%

RGC -5.03%

RMTI -3.41%

SCTL 0.92%

SCYX -3.91%

SIGA -1.58%

SISI -15.00%

SNDL 0.53%

SNOA 2.59%

SSIC -2.87%

SUPN -1.27%

SXTC 1.39%

THTX 1.41%

TKNO -10.22%

TLGT -13.85%

TLRY 1.20%

TXMD 3.05%

TYHT -3.90%

UPC 3.75%

VTRS -0.61%

ZYNE 2.36%

Insider Trading

Date	Person	Action	Amount	type
2024-06-28	Baker Bros. Advisors Lp	Buy	0	Common Stock
2024-06-28	Baker Bros. Advisors Lp	Buy	0	Common Stock
2024-06-28	Baker Bros. Advisors Lp	Buy	263 900	Series F Preferred
2024-06-28	Baker Bros. Advisors Lp	Buy	207 300	Series H Preferred
2024-06-28	Baker Bros. Advisors Lp	Buy	982 600	Series G Preferred

INSIDER POWER
84.03
Last 94 transactions
Buy: 1 241 312 \| Sell: 68 032

Korrelasjon (AI algo v.1.1b): Overvalued: -0.49% $7.02 paired level. (Algoen sporer endringene til de mest korrelerte aksjene i sanntid og gir umiddelbar oppdatering)

Volum Korrelasjon

Lang: -0.16 (neutral)

Kort: 0.47 (neutral)

Signal:(59.897) Neutral

Kala Pharmaceuticals Inc Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Kala Pharmaceuticals Inc Korrelasjon - Valuta/Råvare

-0.20
( neutral )

-0.21
( neutral )

0.00
( neutral )

-0.34
( neutral )

0.00
( neutral )

0.56
( weak )

Kala Pharmaceuticals Inc Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-303 000 (0.00 %)
EPS:	$-17.35

FY	2023
Omsetning:	$0
Bruttogevinst:	$-303 000 (0.00 %)
EPS:	$-17.35

FY	2022
Omsetning:	$3.89M
Bruttogevinst:	$1.33M (34.22 %)
EPS:	$-0.150

FY	2021
Omsetning:	$11.24M
Bruttogevinst:	$7.14M (63.55 %)
EPS:	$-136.13

Financial Reports:

No articles found.

Kala Pharmaceuticals Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Kala Pharmaceuticals Inc

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.